AlphaStocks
5.4
Consider Buy

Pacira BioSciences, Inc. (PCRX)

As of Sep 20, 2026, Pacira BioSciences, Inc. (PCRX) scores 5.4/10 on AlphaStocks' five-model composite, #81 of 168 Health Care stocks. At $25, PCRX trades 90% above its model fair value of $13.

Health Care / Pharmaceuticals

S&P SmallCap 600

$24.70

Below average on several measures. Research carefully.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#81out of 168 in Health Care

Is Pacira BioSciences, Inc. a Good Investment in 2026?

Pacira BioSciences, Inc. (PCRX) scores 5.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates Pacira BioSciences, Inc. as Strong (9/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 1.4% · ROC 3%. Pacira BioSciences, Inc. currently trades 90% above its estimated fair value of $13. Pacira BioSciences, Inc. ranks #81 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E158.2ROE0.7Market Cap1B

Estimated Fair Value

$13.0190% above

Trading above estimated fair value. P/e of 158x implies high growth expectations.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

9/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Neutral

PEG 3.7 · Fast Grower

Greenblatt

Caution

Earnings yield 1.4% · ROC 3%

Frequently Asked Questions

Is Pacira BioSciences, Inc. (PCRX) a good investment?
As of Sep 20, 2026, Pacira BioSciences, Inc. (PCRX) scores 5.4/10 on AlphaStocks' five-model composite, #81 of 168 Health Care stocks. At $25, PCRX trades 90% above its model fair value of $13. That score is below average, suggesting caution.
What is Pacira BioSciences, Inc.'s Piotroski F-Score?
Pacira BioSciences, Inc.'s Piotroski F-Score status is Strong. The raw score is 9/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is PCRX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $13, PCRX appears overvalued. The stock currently trades 90% above its estimated fair value. Trading above estimated fair value. P/e of 158x implies high growth expectations.
How does PCRX compare to other Health Care stocks?
Pacira BioSciences, Inc. ranks #81 out of 168 stocks in the Health Care sector, placing it in the top 48% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about PCRX?
AlphaStocks evaluates PCRX using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 5.4/10.

Similar Stocks

AMPHLLYACAD

Compare PCRX with

AMPH vs PCRXLLY vs PCRXACAD vs PCRX

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer